A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
A phase 2 trial of Tinengotinib, Cadonilimab, Ivonescimab in hepatocellular carcinoma, run by Akeso, now recruiting.
Overview
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. is a phase 2 interventional study registered as NCT07052253 by Akeso, with 100 participants planned, started 2025-07-18 and due to reach its primary completion in 2027-05-10. Interventions recorded: TT-00420 (tinengotinib), AK104, AK112. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Cadonilimab, Ivonescimab, Akeso, Hepatocellular carcinoma.
- TrialA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Akeso.
- TrialA Study of Ivonescimab in First-Line ES-SCLC
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Cadonilimab, Ivonescimab, Akeso.